Sushma Shivaswamy - 10 Feb 2023 Form 4 Insider Report for XBiotech Inc. (XBIT)

SEC form
4
Accepted by SEC
17 Feb 2023, 19:00:49 UTC
Prior SEC filing
23 Nov 2021
Source filing
View source filing
Filing notes and source

Key filing fact

Sushma Shivaswamy filed Form 4 for XBiotech Inc. (XBIT) on 17 Feb 2023.

Key facts

  • This page summarizes Sushma Shivaswamy's Form 4 filing for XBiotech Inc. (XBIT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 17 Feb 2023, 19:00.

Change

  • Previous filing in this sequence was filed on 23 Nov 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XBIT transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
$0
Shares
+100,000
Change %
Price
$0.000000
Shares after
100,000
Date
10 Feb 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$3.84
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .